newsfilter
← Latest News
GlobeNewswire·

Aridis Meets Primary and Secondary Endpoints in Phase 2a Study of AR-501 in Cystic Fibrosis Patients

The study achieved high uptake of AR-501 in the respiratory tract at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa LOS GATOS, Calif., March 13, 2023 (GLOBE